07:00 , Apr 19, 1999 |  BC Week In Review  |  Company News

CarboMed other research news

CarboMed researchers reported the cloning of CM201, a seven transmembrane domain receptor that binds the company's CM101 multi-repeat polysaccharide angiogenesis inhibitor. Data were presented at the American Association for Cancer Research meeting in Philadelphia. CM101...
08:00 , Dec 14, 1998 |  BC Week In Review  |  Company News

CarboMed management update

CarboMed Inc., Brentwood, Tenn.   Business: Cancer   Hired: John Watson as president and CEO, formerly COO of GalaGen Inc.  ...
08:00 , Nov 2, 1998 |  BC Week In Review  |  Clinical News

CarboMed preclinical data

Vanderbilt University researchers reported in the Proceedings of the National Academy of Sciences that CM101, an angiogenesis inhibitor under investigation to treat cancer, allowed mice paralyzed by a spinal cord crush injury to walk again...
08:00 , Nov 2, 1998 |  BioCentury  |  Tools & Techniques

Angiogenesis agent shows healing properties

A compound in Phase I testing for cancer anti-angiogenesis shows exceptional promise as an all-around healer, allowing paralyzed mice to walk again. CarboMed Inc. (Nashville, Tenn.) has licensed the agent to Zeneca Group plc (London,...